Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 3/20 | 0.57 |
| ▸ | CA1 | P00915 | 1/20 | 0.54 |
| ▸ | CAPN1 | P07384 | 6/20 | 0.54 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.53 |
| ▸ | HPGDS | O60760 | 2/20 | 0.53 |
| ▸ | CTSL | P07711 | 3/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.51 |
| ▸ | CTSB | P07858 | 1/20 | 0.50 |
| ▸ | CTSS | P25774 | 1/20 | 0.50 |
| ▸ | CTSK | P43235 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8443478 | 0.90 | CTSL (0.62) | CA2CA1CAPN1PTPN1HPGDS | |
| SCHEMBL27002688 | 0.89 | HPGDS (0.65) | CA2CA1PTPN1HPGDSCTSL | |
| SCHEMBL2105972 | 0.89 | HPGDS (0.65) | CA2CA1PTPN1HPGDSCTSL | |
| SCHEMBL24008817 | 0.89 | HPGDS (0.65) | CA2CA1CAPN1PTPN1HPGDS | |
| SCHEMBL2975803 | 0.86 | PTPN1 (0.70) | CA2CA1PTPN1CTSLRAB9A | |
| SCHEMBL2975807 | 0.86 | PTPN1 (0.70) | CA2CA1PTPN1CTSLRAB9A | |
| SCHEMBL24008816 | 0.86 | HPGDS (0.57) | CAPN1HPGDSCTSLKMT2ACTSB | |
| SCHEMBL29961883 | 0.86 | HPGDS (0.57) | CAPN1HPGDSCTSLKMT2ACTSB | |
| SCHEMBL29189824 | 0.84 | GAA (0.71) | CA2CTSLRAB9AKMT2AGAA | |
| SCHEMBL29189822 | 0.84 | GAA (0.71) | CA2CTSLRAB9AKMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220347173-A1 | METHODS OF TREATING LIVER FIBROSIS USING CALPAIN INHIBITORS | BLADE THERAPEUTICS INC (US) | 2022-11-03 | — | — | US | disclosed |
| US-20210347727-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | BLADE THERAPEUTICS, INC. | 2021-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210347727-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | CAPN1, CAPNS1, CAPN2 | CA2 273/4885CA1 1245/4885CAPN1 1/4885 |
| US-20220347173-A1 | METHODS OF TREATING LIVER FIBROSIS USING CALPAIN INHIBITORS | CAPNS1, CAPN9, CAPN2 | CA2 451/4885CA1 1681/4885CAPN1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.